- Stephen Miller’s fake hair is almost as bad as his policies Sunday 8:00 PM
- California no longer plans to tax your text messages Sunday 6:45 PM
- Insurance company to ‘reevaluate’ relationship with Tucker Carlson after racist comment Sunday 3:59 PM
- Netflix’s instant rewind button is not popular with users Sunday 2:20 PM
- Offset interrupted Cardi B’s set at Rolling Loud Festival, and fans are pissed Sunday 1:18 PM
- ‘Ms. Marvel’ gets a new, award-winning writer in Saladin Ahmed Sunday 11:32 AM
- ‘SNL’ gives us the daddy pageant we’ve been dying for Sunday 10:28 AM
- How pranksters fooled the internet in 2018 Sunday 8:00 AM
- 2018 belonged to trans people Sunday 6:30 AM
- How to watch local channels on Roku Sunday 6:30 AM
- How to watch Levante vs. Barcelona online for free Sunday 6:19 AM
- How to watch Liverpool vs. Manchester United online for free Sunday 6:00 AM
- The best couch co-op video games for couples Sunday 6:00 AM
- Pete Davidson is OK and at work following alarming Instagram post Saturday 7:26 PM
- Wisconsin Governor Scott Walker doesn’t know how to use a Venn diagram Saturday 5:38 PM
It’s unclear if young blood even makes a difference.
A startup called Ambrosia Medical plans to open its first clinic in New York City later this year, and it has an unusual aim: to fill patient veins with blood from more youthful donors.
For $8,000, Ambrosia Medical patrons can undergo a procedure that gives them an infusion of young blood, according to Business Insider. The belief is that in doing this, it can help slow the aging process, giving new life to old organs. The idea has also been parodied on TV in the HBO show Silicon Valley.
Ambrosia Medical conducted a clinical trial in the U.S. in 2017 studying whether this theory is accurate, but the results of that trial haven’t been made public yet. Still, company founder Jesse Karmazin told Business Insider that the results so far have been “really positive.” Anecdotally, recipients felt like they had better sleep, focus, and memory following a transfusion of young blood, as well as improved muscle tone. Those claims are not yet backed up with data, though.
Since Ambrosia Medical is giving patents a blood transfusion (or a plasma transfusion, specifically), a procedure approved by the FDA, it doesn’t face a unique or difficult approval process before opening its doors. According to CDC data, more than 14.5 million blood transfusions take place each year, and typically, recipients don’t experience any ill effects. However, proof from clinical trials could help boost business, adoption, and interest in the idea of using young blood to rejuvenate the older body.
Thus far, David Cavalier, Ambrosia’s chief operating officer, says that Ambrosia Medical has had about 150 patients, 81 of which participated in its clinical trial. Recipients have ranged in age from 35 to 92, while blood donors range in age from 16 to 25.
Ambrosia Medical’s website, which went live last week, is sparse. It consists primarily of a list of addresses where interested parties can email for more information, or you can be added to a waitlist to undergo an $8,000 transfusion.
H/T Business Insider
Christina Bonnington is a tech reporter who specializes in consumer gadgets, apps, and the trends shaping the technology industry. Her work has also appeared in Gizmodo, Wired, Refinery29, Slate, Bicycling, and Outside Magazine. She is based in the San Francisco Bay Area and has a background in electrical engineering.